Xuezhong Yang
Hematology & Oncology · Greenville, SCNPI 1598922650
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,247 of the $1,483 with a category attached, or 84.1%. It is spread thinly across 26 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $766 and has fallen 73.0% since, to $207 in 2024. That places this record below the midpoint for hematology & oncology clinicians in SC, where the typical reported total is $4,020.
Across 67 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Adaptive Biotechnologies Corporation$281
- Astellas Pharma US Inc$254
- Sanofi$120
- Taiho Oncology, Inc.$93
- Merck$84
- Pfizer$73
- plus $578 from 20 others
Across 69 payments — averaging $12,596 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$357K
- E.r. Squibb & Sons, L.L.C.$286K
- Exelixis Inc.$100K
- AbbVie$47K
- AstraZeneca$42K
- Amgen$26K
- plus $13K from 1 others
What the payments were for
- Food & beverage$1,24784%
- Education$23616%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Adaptive Biotechnologies Corporation | 2 | $281 |
| Astellas Pharma US Inc | 9 | $254 |
| Sanofi | 6 | $120 |
| Taiho Oncology, Inc. | 5 | $93 |
| Merck | 6 | $84 |
| Pfizer | 6 | $73 |
| Boston Scientific | 1 | $63 |
| Incyte Corporation | 4 | $60 |
| E.r. Squibb & Sons, L.L.C. | 4 | $52 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $46 |
| Tersera Therapeutics LLC | 2 | $43 |
| Amgen | 2 | $36 |
| Bristol Myers Squibb | 2 | $32 |
| Genentech USA, Inc. | 2 | $28 |
| Servier Pharmaceuticals LLC | 1 | $25 |
| Eisai Inc. | 1 | $24 |
| Acrotech Biopharma Inc. | 1 | $23 |
| AbbVie | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Clovis Oncology, Inc. | 2 | $21 |
| Verastem, Inc. | 1 | $16 |
| Secura Bio, Inc. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
| Novartis | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- clonoSEQ$281
How this compares
$1,483 in reported general payments places this provider in the 20th percentile of 166 hematology & oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 42 | $703,463 |
| BrukinsaZanubrutinib | 41 | $507,626 |
| Lenalidomide | 31 | $447,789 |
| ErleadaApalutamide | 24 | $343,812 |
| Abiraterone Acetate | 80 | $319,105 |
| RevlimidLenalidomide | 11 | $141,542 |
| Sunitinib Malate | 12 | $109,713 |
| EliquisApixaban | 93 | $60,189 |
| XareltoRivaroxaban | 22 | $18,485 |
| Imatinib Mesylate | 19 | $5,918 |
| Prochlorperazine Maleate | 81 | $2,336 |
| Ondansetron Hcl | 91 | $1,401 |
| Hydroxyurea | 36 | $1,298 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 80 | $996 |
| Anastrozole | 30 | $931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada, Xarelto | $11 | $362,29746 claims |
| Bristol Myers SquibbRevlimid | $32 | $141,54211 claims |
| PfizerEliquis | $73 | $60,18993 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 166 hematology & oncology providers in South Carolina.
Other hematology & oncology in Greenville
- Suzanne FanningGreenville$927K
- Stephen DyarGreenville$413K
- Bhumika PatelGreenville$225K
- Joe StephensonGreenville$57K
- Elizabeth CullGreenville$16K
- Kevin KoehlerGreenville$10K
- Paige GanemGreenville$9K
- Vikas DemblaSpartanburg$568K
- Kashyap PatelRock Hill$379K
- Tondre BuckSpartanburg$366K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.